Dr Reddy's Laboratories Launches Lamotrigine Orally Disintegrating Tablets in US Market

Hyderabad : Dr. Reddy’s Laboratories Ltd.announced that it has launched Lamotrigine Orally Disintegrating Tablets in 25 mg, 50 mg, 100 mg, and 200 mg, a therapeutic equivalent generic version of Lamictal^® ODT (lamotrigine) Orally Disintegrating Tablets in the United States market approved by the U.S. Food & Drug Administration (USFDA).

The Lamictal^® ODT brand and generic had U.S. sales of approximately $65.5 million MAT for the most recent twelve months ending in July 2016 according to IMS Health*.

Dr. Reddy’s Lamotrigine Orally Disintegrating Tablets 25 mg, 50 mg, 100 mg, and 200 mg are available in bottle count sizes of 30s.

Lamictal^® ODT is a registered trademark of GSK group of companies.

*IMS National Sales Perspective: Retail and Non-Retail MAT July 2016

RDY-0916-131